CD28 Homodimer Interface Mimetic Peptide Acts as a Preventive and Therapeutic Agent in Models of Severe Bacterial Sepsis and Gram-Negative Bacterial Peritonitis
Open Access
- 9 October 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 211 (6) , 995-1003
Abstract
Background. Severe gram-negative bacterial infections and sepsis are major causes of morbidity and mortality. Dysregulated, excessive proinflammatory cytokine expression contributes to the pathogenesis of sepsis. A CD28 mimetic peptide (AB103; previously known as p2TA) that attenuates CD28 signaling and T-helper type 1 cytokine responses was tested for its ability to increase survival in models of polymicrobial infection and gram-negative sepsis. Methods. Mice received AB103, followed by an injection of Escherichia coli 0111:B4 lipopolysaccharide (LPS); underwent induction E. coli 018:K1 peritonitis induction, followed by treatment with AB103; or underwent cecal ligation and puncture (CLP), followed by treatment with AB103. The effects of AB103 on factors associated with and the lethality of challenge infections were analyzed. Results. AB103 strongly attenuated induction of tumor necrosis factor α and interleukin 6 (IL-6) by LPS in human peripheral blood mononuclear cells. Receipt of AB103 following intraperitoneal injection of LPS resulted in survival among 73% of CD1 mice (11 of 15), compared with 20% of controls (3 of 15). Suboptimal doses of antibiotic alone protected 20% of mice (1 of 5) from E. coli peritonitis, whereas 100% (15 of 15) survived when AB103 was added 4 hours following infection. Survival among mice treated with AB103 12 hours after CLP was 100% (8 of 8), compared with 17% among untreated mice (1 of 6). In addition, receipt of AB103 12 hours after CLP attenuated inflammatory cytokine responses and neutrophil influx into tissues and promoted bacterial clearance. Receipt of AB103 24 hours after CLP still protected 63% of mice (5 of 8). Conclusions. Single-dose AB103 reduces mortality in experimental models of polymicrobial and gram-negative bacterial infection and sepsis, warranting further studies of this agent in clinical trials.Keywords
Funding Information
- National Institutes of Health (2U54AI057168)
This publication has 26 references indexed in Scilit:
- CD28: Direct and Critical Receptor for Superantigen ToxinsToxins, 2013
- A Peptide Antagonist of CD28 Signaling Attenuates Toxic Shock and Necrotizing Soft-Tissue Infection Induced by Streptococcus pyogenesThe Journal of Infectious Diseases, 2013
- Binding of Superantigen Toxins into the CD28 Homodimer Interface Is Essential for Induction of Cytokine Genes That Mediate Lethal ShockPLOS Biology, 2011
- DEFICIENCY OF BID PROTEIN REDUCES SEPSIS-INDUCED APOPTOSIS AND INFLAMMATION, WHILE IMPROVING SEPTIC SURVIVALShock, 2010
- PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsisProceedings of the National Academy of Sciences, 2009
- Recommended tests for association in 2×2 tablesStatistics in Medicine, 2009
- CD40 and CD80/86 Act Synergistically to Regulate Inflammation and Mortality in Polymicrobial SepsisAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008Critical Care Medicine, 2008
- SOCS-1 is a central mediator of steroid-increased thymocyte apoptosis and decreased survival following sepsisApoptosis, 2007
- Active Immunization with a Detoxified Endotoxin Vaccine Protects against Lethal Polymicrobial Sepsis: Its Use with CpG Adjuvant and Potential MechanismsThe Journal of Infectious Diseases, 2005